Orion Oyj is a Finland‐based integrated pharmaceutical and chemical company that develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients (APIs) and diagnostic tests. Its product portfolio spans central nervous system (CNS) agents, oncology treatments, respiratory medicines, cardiovascular drugs and veterinary products. Orion’s proprietary brands include Stalevo for Parkinson’s disease, Simdax for acute heart failure and Dexdor for intensive care sedation, alongside a range of generic APIs supplied to customers worldwide.
Founded in 1917 by pharmacist Onni Turpeinen and Professor E.J. Talvio, Orion has grown from a small Helsinki laboratory into one of Finland’s leading pharmaceutical exporters. Over the decades, the company has built deep expertise in drug synthesis and formulation, pioneering developments in levodopa treatments during the mid-20th century. Orion’s long history of innovation has been underpinned by steady investment in research and development, enabling the company to advance both in‐house projects and partnered programs.
Orion serves customers in more than 100 countries, with strong market positions in the Nordic region, Central and Eastern Europe and parts of Western Europe. International partnerships extend Orion’s reach into North America and the Asia-Pacific region through licensing agreements and distribution deals. The company’s R&D and manufacturing operations are concentrated in Finland, notably in Espoo and Turku, where it maintains state-of-the-art facilities for chemical synthesis, clinical development and quality control.
Since January 2018, Orion has been led by President and Chief Executive Officer Timo Lappalainen, who has overseen a strategic focus on specialty pharmaceuticals and novel chemical compounds. Under Lappalainen’s leadership, the company continues to advance a pipeline of CNS and oncology candidates while pursuing sustainable manufacturing practices. Orion’s long-term strategy emphasizes close collaboration with research institutions, selective in-licensing of promising molecules and commercial partnerships to bring innovative therapies to patients worldwide.
AI Generated. May Contain Errors.
Free ORINF Stock Alerts